Sun Young Kim1, Charny Park2, Ha-Jung Kim3, Jihyun Park1, Jinha Hwang4, Jong-Il Kim5, Min Gew Choi6, Sung Kim6, Kyoung-Mee Kim7, Myung-Soo Kang8. 1. Samsung Advanced Institute for Health Sciences and Technology, Center for Future Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Biomedical Research Institute, Center for Future Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Ewha Research Center for Systems Biology, Ewha Womans University, Seoul, Korea. 3. Samsung Advanced Institute for Health Sciences and Technology, Center for Future Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea. 5. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea; Department of Biochemistry, Seoul National University College of Medicine, Seoul, Korea; Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea. 6. Department of Surgery, Center for Gastric Cancer, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 7. Samsung Biomedical Research Institute, Center for Future Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: kkmkys@skku.edu. 8. Samsung Advanced Institute for Health Sciences and Technology, Center for Future Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Biomedical Research Institute, Center for Future Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: mkang@skku.edu.
Abstract
BACKGROUND & AIMS: Patients with Epstein-Barr virus-associated gastric carcinoma (EBVaGC) have a better prognosis than those with gastric cancer not associated with EBV infection (EBVnGC). This is partly because EBV infection recruits lymphocytes, which infiltrate the tumor. A high degree of tumor heterogeneity is likely to be associated with poor response. We investigated differences in gene expression patterns between EBVaGC and EBVnGC. METHODS: We used gene expression profile analysis to compare tumor and nontumor gastric tissues from 12 patients with EBVaGC and 14 patients with EBVnGC. Findings were validated by whole transcriptome RNAseq and real-time quantitative polymerase chain reaction analyses. CD3(+) primary T cells were isolated from human blood samples; migration of these cells and of Jurkat cells were measured in culture with EBV-infected and uninfected gastric cancer cells. RESULTS: Based on Pearson correlation matrix analysis, EBVaGCs had a higher degree of homogeneity than EBVnGCs. Although 4550 genes were differentially expressed between tumor and nontumor gastric tissues of patients with EBVnGC, only 186 genes were differentially expressed between tumor and nontumor gastric tissues of patients with EBVaGC (P < .001). This finding supports the concept that EBVaGCs have fewer genetic and epigenetic alterations than EBVnGCs. Expression of major histocompatibility complex class II genes and genes that regulate chemokine activity were more often deregulated in EBVaGCs compared with nontumor tissues. In culture, more T cells migrated to EBV-infected gastric cancer cells than to uninfected cells; migration was blocked with a neutralizing antibody against CXCR3 (a receptor for many chemokines). CONCLUSIONS: Fewer genes are deregulated in EBVaGC than in EBVnGC. Most changes in EBVaGCs occur in immune response genes. These changes might allow EBVaGC to recruit reactive immune cells; this might contribute to the better outcomes of these patients compared with those with EBVnGC.
BACKGROUND & AIMS:Patients with Epstein-Barr virus-associated gastric carcinoma (EBVaGC) have a better prognosis than those with gastric cancer not associated with EBV infection (EBVnGC). This is partly because EBV infection recruits lymphocytes, which infiltrate the tumor. A high degree of tumor heterogeneity is likely to be associated with poor response. We investigated differences in gene expression patterns between EBVaGC and EBVnGC. METHODS: We used gene expression profile analysis to compare tumor and nontumor gastric tissues from 12 patients with EBVaGC and 14 patients with EBVnGC. Findings were validated by whole transcriptome RNAseq and real-time quantitative polymerase chain reaction analyses. CD3(+) primary T cells were isolated from human blood samples; migration of these cells and of Jurkat cells were measured in culture with EBV-infected and uninfected gastric cancer cells. RESULTS: Based on Pearson correlation matrix analysis, EBVaGCs had a higher degree of homogeneity than EBVnGCs. Although 4550 genes were differentially expressed between tumor and nontumor gastric tissues of patients with EBVnGC, only 186 genes were differentially expressed between tumor and nontumor gastric tissues of patients with EBVaGC (P < .001). This finding supports the concept that EBVaGCs have fewer genetic and epigenetic alterations than EBVnGCs. Expression of major histocompatibility complex class II genes and genes that regulate chemokine activity were more often deregulated in EBVaGCs compared with nontumor tissues. In culture, more T cells migrated to EBV-infected gastric cancer cells than to uninfected cells; migration was blocked with a neutralizing antibody against CXCR3 (a receptor for many chemokines). CONCLUSIONS: Fewer genes are deregulated in EBVaGC than in EBVnGC. Most changes in EBVaGCs occur in immune response genes. These changes might allow EBVaGC to recruit reactive immune cells; this might contribute to the better outcomes of these patients compared with those with EBVnGC.
Authors: Shu Su; Zhengyun Zou; Fangjun Chen; Naiqing Ding; Juan Du; Jie Shao; Lin Li; Yao Fu; Bian Hu; Yang Yang; Huizi Sha; Fanyan Meng; Jia Wei; Xingxu Huang; Baorui Liu Journal: Oncoimmunology Date: 2016-11-22 Impact factor: 8.110
Authors: Charny Park; Junhun Cho; Jeeyun Lee; So Young Kang; Ji Yeong An; Min Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Sung Kim; Seung Tae Kim; Se Hoon Park; Joon Oh Park; Won Ki Kang; Insuk Sohn; Sin Ho Jung; Myung-Soo Kang; Kyoung-Mee Kim Journal: Oncoimmunology Date: 2017-08-10 Impact factor: 8.110
Authors: Mohamad El-Zaatari; Adam J Bass; Reanne Bowlby; Min Zhang; Li-Jyun Syu; Yitian Yang; Helmut Grasberger; Andrew Shreiner; Bei Tan; Shrinivas Bishu; Wai K Leung; Andrea Todisco; Nobuhiko Kamada; Marilia Cascalho; Andrzej A Dlugosz; John Y Kao Journal: Gastroenterology Date: 2017-09-11 Impact factor: 22.682
Authors: Namrata Setia; Agoston T Agoston; Hye S Han; John T Mullen; Dan G Duda; Jeffrey W Clark; Vikram Deshpande; Mari Mino-Kenudson; Amitabh Srivastava; Jochen K Lennerz; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers Journal: Mod Pathol Date: 2016-04-01 Impact factor: 7.842